CHIH


MSCI China Health Care ETF

Fund Summary

The Global X MSCI China Health Care ETF (CHIH) seeks to invest in large- and mid-capitalization segments of the MSCI China Index that are classified in the Health Care Sector as per the Global Industry Classification System (GICS).

Fund Objective

The Global X MSCI China Health Care ETF (CHIH) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the MSCI China Health Care 10/50 Index.

Why CHIH?

Targeted Exposure

CHIH is a targeted play on the Health Care Sector in China – the world’s second largest economy by GDP.

ETF Efficiency

In a single trade, CHIH delivers access to dozens of health care companies within the MSCI China Index, providing investors an efficient vehicle to express a sector view on China.

All Share Exposure

The Index incorporates all eligible securities as per MSCI’s Global Investable Market Index Methodology, including China A, B and H shares, Red chips, P chips and foreign listings, among others.

Fund Details As of 07/28/21

Key Facts

Ticker CHIH
Inception Date 12/07/18
CUSIP 37954Y541
ISIN US37954Y5419
Bloomberg Index Ticker NU722071
Primary Exchange NYSE Arca
Number of Holdings 89

Stats & Fees

Net Assets $18,584,094
Net Asset Value (NAV) $27.74
Shares Outstanding 670,002
Total Expense Ratio 0.65%

Distributions

30-Day SEC Yield -0.15%
Distribution Frequency Semi-Annually

Fund Prices As of 07/28/21

NAV $27.74 Daily Change $2.00 7.79%
Market Price $28.30 Daily Change $2.80 10.98%
30-Day Median Bid-Ask Spread 0.74%

Performance History

As of recent month & quarter-end (06/30/21)
As of recent month & quarter-end (06/30/21)
Fund NAV Market Price Index
1 Year 41.18% 39.40% 42.28%
Since Inception 36.34% 36.21% 37.39%
1 Year 41.18% 39.40% 42.28%
Since Inception 36.34% 36.21% 37.39%
Year-to-Date 22.28% 23.22% 22.67%
1 Month 3.72% 3.11% 0.90%
3 Months 19.66% 18.89% 19.85%
Since Inception 121.44% 120.91% 125.82%
Year-to-Date 22.28% 23.22% 22.67%
1 Month 3.72% 3.11% 0.90%
3 Months 19.66% 18.89% 19.85%
Since Inception 121.44% 120.91% 125.82%

Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance of the Fund, when observed, is unusual and investors should not expect such performance to be repeated.

Fund Characteristics As of 07/28/21

Return on Equity 9.10%
Weighted Avg. Market Cap 13,024 M
2020 2021
Price-to-earnings 69.27 48.08
Price-to-book value 4.51 4.26

Source: AltaVista Research, LLC

Fund Risk Stats As of 07/28/21

Versus Beta
S&P 500 0.55
MSCI EAFE 0.49
MSCI Emg. Mkts 0.72
Standard Deviation 23.70%

Source: AltaVista Research, LLC

Top Holdings As of 07/28/21

Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
10.97 2269 HK WUXI BIOLOGICS CAYMAN INC BL6B9P1 15.31 133,180 2,039,098.32
6.78 BGNE BEIGENE LTD-ADR BYYWPW6 312.71 4,027 1,259,283.17
5.75 1093 HK CSPC PHARMACEUTI 6191997 1.30 823,208 1,068,853.91
5.33 ZLAB ZAI LAB LTD-ADR BD9GVY0 142.63 6,950 991,278.50
5.00 1801 HK INNOVENT BIOLOGICS INC BGR6KX5 9.67 96,200 929,994.34
4.30 1177 HK SINO BIOPHARMACEUTICAL B00XSF9 0.83 958,400 799,611.25
3.73 2359 HK WUXI APPTEC CO LTD-H BGHH0L6 22.23 31,176 692,951.41
2.75 1548 HK GENSCRIPT BIOTECH CORP BD9Q2J2 4.17 122,700 511,065.97
2.71 241 HK ALIBABA HEALTH BRXVS60 1.35 373,300 503,888.77
2.52 853 HK MICROPORT SCIENTIFIC CORP B676TW7 7.29 64,200 467,956.50
2.31 1066 HK SHANDONG WEIG-H 6742340 1.76 244,300 429,632.33
2.22 300760 C2 SHENZHEN MINDR-A BHQK864 63.71 6,461 411,610.55
2.22 1833 HK PING AN HEALTHCA BDRYVB3 8.97 45,900 411,570.55
2.20 3692 HK HANSOH PHARMACEU BJYKB72 3.46 118,300 409,095.23
2.19 2196 HK FOSUN PHARMA-H B8XBQ96 7.75 52,400 406,196.33
2.10 HCM HUTCHMED CHINA-ADR BYXV9H7 41.81 9,352 391,007.12
1.97 1099 HK SINOPHARM GROUP CO-H B3ZVDV0 2.67 137,400 366,515.40
1.90 603259 C1 WUXI APPTEC CO LTD-A BHWLWV4 23.51 15,024 353,269.25
1.82 600276 C1 JIANGSU HENGRU-A BP3R369 8.60 39,272 337,885.39
1.75 867 HK CHINA MEDICAL SY B6WY993 2.16 150,300 324,991.77
1.69 300015 C2 AIER EYE HSPTL-A BD5CLQ4 8.85 35,524 314,385.20
1.39 600436 C1 ZHANGZHOU PIEN-A BP3R7Z6 58.17 4,426 257,467.90
1.37 6185 HK CANSINO BIOLOGICS INC-H BJKDJS2 37.51 6,800 255,083.05
1.32 3759 HK PHARMARON BEIJ-H BK72QD3 21.56 11,350 244,690.06
1.21 300122 C2 CHONGQING ZHIF-A BD5CJY8 23.39 9,633 225,321.20
1.15 3347 HK HANGZHOU TIGER-H BMZC7F8 19.60 10,920 214,081.86
1.15 570 HK TRAD CHI MED 6971779 0.60 359,100 213,739.01
1.12 1951 HK JINXIN FERTILITY BJ9JY53 1.77 117,700 208,503.37
1.09 2607 HK SHANGHAI PHARM-H B4Q4CJ6 2.09 97,400 203,094.05
0.84 000538 C2 YUNNAN BAIYAO-A BD5CP95 15.47 10,110 156,355.84
0.83 600196 C1 SHANGHAI FOSUN-A BP3R3M5 10.83 14,274 154,527.83
0.76 1530 HK 3SBIO INC BY9D3L9 0.85 166,200 140,800.38
0.72 2005 HK SSY GROUP LTD BYP9J68 0.63 213,500 134,212.86
0.71 IMAB I-MAB-SPONSORED ADR BKRRKY7 73.76 1,800 132,768.00
0.65 3320 HK CHINA RESOURCES BYNGG26 0.53 229,500 121,553.45
0.65 000661 C2 CHANGCHUN HIGH-A BD5CDB3 47.85 2,528 120,958.56
0.64 300142 C2 WALVAX BIOTECHNOLOGY CO-A BD5CG36 11.16 10,700 119,392.92
0.61 300347 C2 HANGZHOU TIGER-A BD5CCK5 24.74 4,616 114,179.11
0.59 600763 C1 TOPCHOICE MEDI-A BYYFJH8 50.27 2,180 109,584.56
0.55 000963 C2 HUADONG MEDICINE CO LTD-A BD5CM94 5.43 18,711 101,640.92
0.49 002821 C2 ASYMCHEM LABOR-A BD6V5C4 60.72 1,513 91,874.06
0.49 9926 HK AKESO INC BLFJ7Y1 6.12 15,000 91,787.94
0.47 300601 C2 SHENZHEN KANGT-A BFY8HT2 19.33 4,543 87,800.04
0.42 600332 C1 GUANGZHOU BAIY-A BP3R4Q6 4.66 16,559 77,159.05
0.40 002007 C2 HUALAN BIOLOGI-A BD5CL19 5.68 13,070 74,216.22
0.39 002001 C2 ZHEJIANG NHU CO LTD-A BD5CH66 4.00 18,240 72,978.53
0.37 2500 HK VENUS MEDTECH -H BL6V047 6.04 11,500 69,409.81
0.37 300595 C2 OVCTEK CHINA INC-A BHQPSJ2 13.57 5,024 68,189.12
0.30 300529 C2 JAFRON BIOMEDI-A BFY8H03 10.53 5,200 54,733.89
0.28 600998 C1 JOINTOWN PHARMACEUTICAL-A BP3R541 2.21 23,370 51,750.72
0.28 002044 C2 MEINIAN ONEHEA-A BD73L10 1.12 45,920 51,443.46
0.28 300003 C2 LEPU MEDICAL TECHNOLOGY-A BD5CM16 3.97 12,901 51,200.20
0.27 603882 C1 GUANGZHOU KING-A BFYX689 18.76 2,700 50,664.86
0.26 600161 C1 BEIJING TIAN-A BP3R9J4 5.69 8,400 47,762.89
0.26 002294 C2 SHENZHEN SALUBRIS PHARM-A BD5CM05 4.23 11,200 47,396.65
0.25 002422 C2 SICHUAN KELUN-A BD5CL08 2.76 17,000 46,958.07
0.24 603858 C1 SHANDONG BUCHA-A BYW5NC3 3.11 14,487 45,121.74
0.24 600867 C1 TONGHUA DONGBA-A BP3R808 1.73 25,305 43,730.35
0.22 BNR BURNING ROCK-ADR BMBKH34 21.87 1,892 41,378.04
0.21 300676 C2 BGI GENOMICS CO LTD-A BFY8H58 16.01 2,433 38,941.63
0.20 000423 C2 DONG-E-E-JIAOCO LTD-A BD5CM61 4.68 7,800 36,465.26
0.20 601607 C1 SHANG PHARM -A BP3R4Z5 2.89 12,600 36,452.33
0.19 300759 C2 PHARMARON BEIJ-A BK4XYC4 31.64 1,100 34,799.30
0.18 002603 C2 SHIJIAZHUANG Y-A BD5CHJ9 2.81 12,027 33,850.72
0.18 002223 C2 JIANGSU YUYUE-A BD5CJM6 5.38 6,100 32,807.56
0.18 300558 C2 BETTA PHARMACE-A BD6QWL7 13.40 2,420 32,439.96
0.17 002252 C2 SHANGHAI RAAS -A BD5CPJ5 1.12 28,800 32,397.15
0.17 600079 C1 HUMANWELL HEAL-A BP3R712 3.48 9,200 32,038.29
0.17 300253 C2 WINNING HEALTH-A BD5CKZ6 2.35 13,470 31,693.63
0.17 300677 C2 INTCO MEDICAL-A BMTCVT6 16.49 1,900 31,328.72
0.17 300357 C2 ZHEJIANG WOLWO-A BFY8GY0 9.59 3,223 30,899.06
0.15 603707 C1 NANJING KING-F-A BF2DZL7 4.41 6,136 27,043.02
0.15 600521 C1 ZHEJIANG HUAHA-A BP3RBR6 2.84 9,510 27,000.62
0.14 000739 C2 APELOA PHARMA-A BD5LY17 4.24 6,100 25,851.79
0.13 002030 C2 DAAN GENE CO LTD-A BD5CKW3 3.06 7,560 23,151.11
0.12 000999 C2 CHINA RESOURCE-A BD5CL42 3.62 6,000 21,743.98
0.11 603658 C1 AUTOBIO DIAGNO-A BYW5N89 9.04 2,282 20,627.49
0.11 CASH 1.00 20,466 20,378.15
0.11 000513 C2 LIVZON PHARM-A BD5CQ25 5.95 3,400 20,237.75
0.10 300482 C2 GUANGZHOU WOND-A BFY8GZ1 8.12 2,390 19,415.41
0.10 600380 C1 JOINCARE PHARM-A BP3RBV0 1.79 10,100 18,060.28
0.10 600511 C1 CHINA NATIONAL-A BP3R9B6 4.50 4,000 17,998.41
0.09 002019 C2 YIFAN PHARMACE-A BD5CDK2 2.08 8,400 17,437.66
0.09 300463 C2 MACCURA BIOTECH CO LTD-A BD5M283 5.60 3,000 16,808.88
0.09 600529 C1 SHANDONG PHAR-A BMVB2W1 5.20 3,200 16,654.07
0.08 000623 C2 JILIN AODONG P-A BD5CLG4 2.31 6,700 15,496.40
0.08 002399 C2 SHENZHEN HEPAL-A BD5CKT0 2.28 6,700 15,279.88
0.08 603127 C1 JOINN LABORATO-A BK94819 30.52 500 15,257.72
0.08 688185 C1 CANSINO BIOLOGICS INC-A BMD9JD3 89.44 165 14,757.54
0.07 603456 C1 ZHEJIANG JIUZH-A BMQBVL8 6.91 1,900 13,127.95
Holdings are subject to change.


Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHIH is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by MSCI, nor does MSCI make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with MSCI.